Skip to main content

Treatment Clinical Trials for Multiple Myeloma/Plasma Cell Myeloma

Review the multiple myeloma/plasma cell myeloma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 189

Mezigdomide plus Ixazomib and Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: 2 locations
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Immune System Cells for the Treatment of Relapse or Refractory Hematological Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients with Relapsed Multiple Myeloma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
CYT107 for the Treatment of Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Carfilzomib-Based Chemotherapy before Autologous Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
CS1-CAR T Therapy following Chemotherapy in Treating Patients with Relapsed or Refractory CS1 Positive Multiple Myeloma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma, BELLA Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Selinexor Maintenance Treatment After CAR-T Cell Therapy (Cilta-cel) for Triple-class Exposed or Refractory Multiple Myeloma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Rifaximin in Treating Patients with Monoclonal Gammopathy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells (1XX BCMA CAR-T cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of California San Francisco, San Francisco, California
Hypofractionation for the Improved Treatment of Osseous or Extra Osseous Lesions in Patients with Newly Diagnosed, Relapsed, or Refractory Multiple Myeloma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Venetoclax and Tocilizumab for the Treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
TriPRIL CAR T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
A Vaccine (DC/MM Fusion Vaccine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Status: Active
Location: 2 locations
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Talquetamab in Combination with Iberdomide and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of California San Francisco, San Francisco, California
WS-CART-CS1 for the Treatment of Patients with Recurrent or Refractory Multiple Myeloma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri